Many docs who tweeted product endorsements also took money from manufacturers, analysis shows

Taking stock of the drug industry, from the lab to the medicine chest

May 30, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Many docs who tweeted product endorsements also took money from manufacturers, analysis shows A new study found 93% of doctors who tweeted about a drug or device received at least one payment from the product's manufacturer. By Ed Silverman STAT+ | Novartis sues Maryland over the role of contract pharmacies in a U.S. drug discount program Novartis argued the Maryland law is illegal because it is preempted by federal law and also violates the U.S. Constitution. By Ed Silverman STAT+ | Clinical lab trade group sues FDA over plan to regulate lab-developed tests The American Clinical Laboratory Association sued the Food and Drug Administration over its plan to regulate lab-developed tests. By Lizzy Lawrence Jonathan Wiggs /Globe Staff STAT+ | Ultragenyx gene therapy for rare liver ailment succeeds in late-stage trial The company's chief medical officer, Eric Crombez, said it now plans to apply for approval with the Food and Drug Administration. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser